ConductScience.org, home

Trial · NCT05457855

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone

NCT05457855, Completed, Brigham and Women's Hospital; results first posted 2025-08-11

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone. Trials, record NCT05457855. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05457855

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone
NCT number
NCT05457855
Status
Completed
Enrollment
51,533 participants, actual
Lead sponsor
Brigham and Women's Hospital
Conditions
Asthma
Interventions
Montelukast, Fluticasone
First posted
2022-07-14
Last updated
2025-08-11
Results first posted
2025-08-11

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryTime to Dementia OnsetMedian follow up times: 1) 161 days (exp), 120 days (ref) 2) 504 days (exp), 638 days (ref) 3) 212 days (exp), 130 days (ref) 4) 162 days (exp), 120 days (ref)
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYTime to Dementia OnsetMedian follow up times: 1) 161 days (exp), 120 days (ref) 2) 504 days (exp), 638 days (ref) 3) 212 days (exp), 130 days (ref) 4) 162 days (exp), 120 days (ref)Incidence rate per 1000 person yearNUMBER

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Time to Dementia OnsetMontelukastAnalysis 19.195% Confidence Interval 7.3 to 11.1Incidence rate per 1000 person year
Time to Dementia OnsetFluticasoneAnalysis 15.695% Confidence Interval 4.0 to 7.7Incidence rate per 1000 person year
Time to Dementia OnsetMontelukastAnalysis 214.595% Confidence Interval 12.1 to 17.2Incidence rate per 1000 person year
Time to Dementia OnsetFluticasoneAnalysis 214.295% Confidence Interval 11.9 to 16.7Incidence rate per 1000 person year
Time to Dementia OnsetMontelukastAnalysis 311.495% Confidence Interval 8.7 to 14.9Incidence rate per 1000 person year
Time to Dementia OnsetFluticasoneAnalysis 38.695% Confidence Interval 5.8 to 12.4Incidence rate per 1000 person year
Time to Dementia OnsetMontelukastAnalysis 43.595% Confidence Interval 2.4 to 4.8Incidence rate per 1000 person year
Time to Dementia OnsetFluticasoneAnalysis 41.895% Confidence Interval 0.97 to 3.1Incidence rate per 1000 person year

Participant flow6

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDMontelukast12,575
Overall StudySTARTEDFluticasone38,958
Overall StudyCOMPLETEDMontelukast12,572
Overall StudyCOMPLETEDFluticasone12,572
Overall StudyNOT COMPLETEDMontelukast3
Overall StudyNOT COMPLETEDFluticasone26,386

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityMontelukast012,569
Total, all-cause mortalityFluticasone012,569
Total, other adverse eventsMontelukast012,569
Total, other adverse eventsFluticasone012,569
Total, serious adverse eventsMontelukast00
Total, serious adverse eventsFluticasone00

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Montelukast vs Fluticasone: deaths from any cause

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05457855

GET https://conductscience.org/api/trials/v1/NCT05457855/registered